Search - tctmd.com

Displaying 461 - 480 of 557

Sort: Relevancy | Date

News Daily News

El Preacondicionamiento Contrarrestaría el Aumento Plaquetario secundario a la Ablación RF en el Manejo de la FA

L.A. McKeown

December 30, 2013

News Daily News

Bivalirudin Lowers Post-PCI Bleeding Risk Across All Renal Dysfunction Categories

December 10, 2013

News Daily News

HORIZONS-AMI: Mortality Reduction with Bivalirudin Only Partially Due to Bleeding

Caitlin E. Cox

November 01, 2013

News Conference News TCT 2013

EUROMAX: Prehospital Bivalirudin Reduces Bleeding in STEMI

October 30, 2013

News Daily News

INFUSE-AMI: Thirty-Day Reduction in Infarct Size May Translate to 1-Year Benefit

Caitlin E. Cox

October 11, 2013

News Daily News

Postconditioning Ineffective in STEMI Patients Receiving Primary PCI

Caitlin E. Cox

September 27, 2013

News Daily News

Baseline White Blood Cell Count Predicts Infarct Size in Anterior STEMI

Yael L. Maxwell

September 27, 2013

News Conference News ESC 2013

PRAMI: Strong Showing for Complete Revascularization in Acute STEMI Patients

Caitlin E. Cox

September 01, 2013

Presentation

Stent Thrombosis with Ticagrelor vs. Clopidogrel in Patients with Acute Coronary Syndromes

Presenter: Philippe Gabriel Steg

August 02, 2013

News Daily News

More Long-term Cardiac Mortality with First-Generation DES vs. BMS for STEMI

July 24, 2013

News Daily News

HORIZONS-AMI: La Bivalirudina y Taxus Mejoran los Resultados en Pacientes sometidos a una PCI en la Arteria Descendente Anterior Izda

Leah Lawrence

July 11, 2013

News Daily News

HORIZONS-AMI: Bivalirudin, Taxus Improve Outcomes in LAD PCI Patients

Leah Lawrence

July 11, 2013

News Conference News EuroPCR 2013

COMFORTABLE-AMI: Biodegradable-Polymer DES Offers Lasting Benefit to STEMI Patients

Caitlin E. Cox

May 23, 2013

News Conference News EuroPCR 2013

PRAGUE-19 Registry: Bioresorbable Scaffolds an Option for Certain STEMI Patients

Caitlin E. Cox

May 22, 2013

News Daily News

Prasugrel Noninferior to Ticagrelor in STEMI, but Both Require Hours to Achieve Effect

Yael L. Maxwell

May 13, 2013

News Daily News

Vorapaxar Substudy Shows Broad MI Reduction in High-Risk ACS Patients

L.A. McKeown

April 19, 2013

News Daily News

Rivaroxaban Added to Dual Antiplatelet Therapy Cuts Stent Thrombosis in ACS Patients

Caitlin E. Cox

April 19, 2013

News Daily News

Rivaroxaban + Terapia Antiplaquetaria Doble Reducen la Trombosis del Stent en Pacientes víctimas de un SCA

Caitlin E. Cox

April 19, 2013

Presentation

Reduction of Stent Thrombosis in ACS Patients Treated with Rivaroxaban in ATLAS ACS 2-TIMI 51

Presenter: C. Michael Gibson

April 17, 2013

News Daily News

SCAAR Turns 20: PCI Expanded to Higher-Risk Patients with No Mortality Trade-off

March 25, 2013

Advertisement

El Preacondicionamiento Contrarrestaría el Aumento Plaquetario secundario a la Ablación RF en el Manejo de la FA

Bivalirudin Lowers Post-PCI Bleeding Risk Across All Renal Dysfunction Categories

HORIZONS-AMI: Mortality Reduction with Bivalirudin Only Partially Due to Bleeding

EUROMAX: Prehospital Bivalirudin Reduces Bleeding in STEMI

INFUSE-AMI: Thirty-Day Reduction in Infarct Size May Translate to 1-Year Benefit

Postconditioning Ineffective in STEMI Patients Receiving Primary PCI

Baseline White Blood Cell Count Predicts Infarct Size in Anterior STEMI

PRAMI: Strong Showing for Complete Revascularization in Acute STEMI Patients

Stent Thrombosis with Ticagrelor vs. Clopidogrel in Patients with Acute Coronary Syndromes

More Long-term Cardiac Mortality with First-Generation DES vs. BMS for STEMI

HORIZONS-AMI: La Bivalirudina y Taxus Mejoran los Resultados en Pacientes sometidos a una PCI en la Arteria Descendente Anterior Izda

HORIZONS-AMI: Bivalirudin, Taxus Improve Outcomes in LAD PCI Patients

COMFORTABLE-AMI: Biodegradable-Polymer DES Offers Lasting Benefit to STEMI Patients

PRAGUE-19 Registry: Bioresorbable Scaffolds an Option for Certain STEMI Patients

Prasugrel Noninferior to Ticagrelor in STEMI, but Both Require Hours to Achieve Effect

Vorapaxar Substudy Shows Broad MI Reduction in High-Risk ACS Patients

Rivaroxaban Added to Dual Antiplatelet Therapy Cuts Stent Thrombosis in ACS Patients

Rivaroxaban + Terapia Antiplaquetaria Doble Reducen la Trombosis del Stent en Pacientes víctimas de un SCA

Reduction of Stent Thrombosis in ACS Patients Treated with Rivaroxaban in ATLAS ACS 2-TIMI 51

SCAAR Turns 20: PCI Expanded to Higher-Risk Patients with No Mortality Trade-off

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content